Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2017 4
2018 2
2019 1
2020 2
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Engineered off-the-shelf therapeutic T cells resist host immune rejection.
Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Mo F, et al. Among authors: srinivasan m. Nat Biotechnol. 2021 Jan;39(1):56-63. doi: 10.1038/s41587-020-0601-5. Epub 2020 Jul 13. Nat Biotechnol. 2021. PMID: 32661440 Free PMC article.
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. Watanabe N, et al. Among authors: srinivasan m. Mol Ther. 2023 Jan 4;31(1):24-34. doi: 10.1016/j.ymthe.2022.09.003. Epub 2022 Sep 9. Mol Ther. 2023. PMID: 36086817 Free PMC article.
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla P, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M. Hill LC, et al. Among authors: srinivasan m. Blood. 2024 Mar 28;143(13):1231-1241. doi: 10.1182/blood.2023022204. Blood. 2024. PMID: 38145560
HMGB1 in hormone-related cancer: a potential therapeutic target.
Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Kalyanasundaram R, Munirathinam G. Srinivasan M, et al. Horm Cancer. 2014 Jun;5(3):127-39. doi: 10.1007/s12672-014-0175-0. Epub 2014 Apr 10. Horm Cancer. 2014. PMID: 24718937 Free PMC article. Review.
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Cabral JMS, Ramos CA, Brenner MK, Mamonkin M. Gomes-Silva D, et al. Among authors: srinivasan m. Mol Ther. 2019 Jan 2;27(1):272-280. doi: 10.1016/j.ymthe.2018.10.001. Epub 2018 Oct 4. Mol Ther. 2019. PMID: 30391141 Free PMC article.
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, Simons BW, McLean Stevens A, Redell MS, Heslop HE, Mamonkin M, Brenner MK, Atilla E. Ataca Atilla P, et al. Among authors: srinivasan m. J Immunother Cancer. 2020 Sep;8(2):e001229. doi: 10.1136/jitc-2020-001229. J Immunother Cancer. 2020. PMID: 32938629 Free PMC article.
11 results